摘要
目的探讨p120及Bmi-1在乳腺浸润性导管癌中的表达及其与临床病理特征的关系。方法采用免疫组化检测135例乳腺浸润性导管癌组织中p120、Bmi-1及ER、PR、c-erbB-2表达情况,并检测了20例乳腺增生症中p120、Bmi-1表达情况。结果 p120异常表达率及Bmi-1高表达率在135例乳腺浸润性导管癌中分别为67.4%和48.1%,在20例乳腺增生症中分别为5%和10%,以上两组之间差异有显著性(P<0.01)。p120异常表达与高组织学分级、淋巴结转移和临床较晚分期均有明显相关性(P<0.05)。Bmi-1高表达与淋巴结转移、临床较晚分期均有明显相关性(P<0.05)。并且,p120异常表达与Bmi-1高表达呈明显正相关(r=0.259,P<0.01)。结论 p120异常表达与Bmi-1高表达在乳腺癌的发生及发展过程中可能发挥了协同或相关的作用。p120与Bmi-1可能成为预测乳腺浸润性导管癌生物学行为及指导靶向治疗的新的分子标记物。
Purpose To investigate the relationship between the expression of p120,Bmi-1 and clinicopathological characteristics in invasive mammary ductal carcinoma.Methods The immunohistochemical staining was performed to detect the expression of p120,Bmi-1 and ER,PR and c-erbB-2 in 135 cases of invasive mammary ductal carcinoma and the expression of p120,Bmi-1 was also detected in 20 cases of mammary adenosis.Results The rate of p120 aberrant expression and Bmi-1 overexpression were 67.4% and 48.1%,respectively,in 135 cases of invasive mammary ductal carcinoma,and that were 5% and 10%,respectively,in 20 cases of mammary adenosis.Significant relationships were found among p120 aberrant expression and high histologic grades,lymph node metastasis and TNM staging(P0.05),and among Bmi-1 overexpression and lymph node metastasis and TNM staging(P0.05).Furthermore,the aberrant expression of p120 was correlated with the overexpression of Bmi-1(r=0.259,P0.01).Conclusion The aberrant expression of p120 and overexpression of Bmi-1 are likely to have synergistic or related effects on the pathogenesis and progression of invasive mammary ductal cancer.p120 and Bmi-1 may serve as new biomarkers for predicting the biological behavior and targeting treatment for patients with invasive mammary ductal carcinoma.
出处
《临床与实验病理学杂志》
CAS
CSCD
北大核心
2011年第8期831-834,共4页
Chinese Journal of Clinical and Experimental Pathology
基金
江苏省南通市社会发展科技计划(S2008013)